March 23, 2026 · Arthritis & rheumatology (Hoboken, N.J.) · DOI: 10.1002/art.70130

Subsets of Lupus Patients Identified by Gene Expression Profiles Exhibit Differential Clinical Responsiveness to Baricitinib

Listen to this summary

The authors aimed to identify subsets of systemic lupus erythematosus (SLE) patients that exhibit differential clinical responsiveness to baricitinib, a JAK1 inhibitor. Through transcriptomic analysis of 272 patients, they identified eight molecular endotypes, with significant clinical responses to baricitinib observed in endotypes D and G. The study highlights that treatment-responsive subsets were not identifiable through clinical features alone, emphasizing the importance of gene expression profiles in predicting therapeutic outcomes.

Prathyusha Bachali, Amrie Grammer, Peter E Lipsky

This is one of 33,000+ journals available on OSLR. Try it free for 14 days.

Free 14-day trial. 33,000+ journals. Cancel anytime.

14-day free trial. No commitment.

"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."

Dr. Jennifer Thompson

Dr. Jennifer Thompson

Portland, OR

Stay current without falling behind

33,000+ journals. 3-minute audio summaries. Free for 14 days.

Download on the App StoreGet it on Google Play